Treatment of pyroptosis
US11752196B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Sep 21, 2020 |
| Grant date | Sep 12, 2023 |
| Priority date | — |
| Expiry date | Sep 21, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/085
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention derives from the unexpected finding that pyroptosis is a novel biomarker and target for therapy in liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Gasdermin D (GSDMD), caspase 4, caspase 5, or Interleukin 1 alpha (IL-1α) can be detected and quantified in serum or plasma, and used as biomarkers for outcome in liver failure such as acute liver failure (ALF) and ACLF and other diseases involving aberrant pyroptosis. By antagonising GSDMD, caspase 4, caspase 5 or Interleukin 1 alpha (IL-1α) many of the unwanted consequences or symptoms of liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of liver failure such as acute liver failure (ALF) and ACLF. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of aberrant pyroptosis in the kidney, brain, liver or other organ of the body.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.